Clinical Trial Update: MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers [Phase 1]

View source ↗

Summary

Adaptimmune's Phase 1 trial of MAGE-A10 CAR T therapy for urothelial carcinoma, head and neck cancer, and melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Melanoma
• Urothelial Carcinoma

Drugs mentioned

• MAGE-A10 CAR T (c797T)

Snippet

Sponsor: Adaptimmune | Conditions: Urothelial Carcinoma, Head and Neck Cancer | Phase 1 | Status: COMPLETED